fbpx Skip to main content

409A Valuation Services for Life Science – Biocom California

Economics Partners

Economics Partners focuses on their client’s success by providing rigorous, well-supported valuation and transfer pricing services. They service multi-billion-dollar public companies, small privately-owned businesses, and everything in-between, and Biocom California members are right in their ‘sweet spot’. EP brings together in one firm some of the most accomplished valuation and transfer pricing professionals with significant experience not only in professional services, but also in running technology and consumer products companies as executives – they understand their clients better than the competition, and they are very high touch when it comes to their approach. Their focus is on helping their clients succeed and they do this by providing best-in-class Transfer Pricing and Valuation services.

Economics Partners provides services at a level of professionalism clients expect from top global professional services at a value Biocom California members have come to expect from the marketplace. Senior leadership includes accomplished professionals and successful entrepreneurs from firms such as EY, PwC, Duff & Phelps, and Jefferies.

Contact your Biocom California representative to find out how you can start taking advantage of this great new program today.

Biocom California Member Benefits

  • Discounted IRC 409A, ASC 718 Stock-Based Compensation and ASC 805 Purchase Price Allocation services
  • Exclusive first-time engagement discounts
  • Exclusive incentives for one-year spend milestones
  • Exclusive incentives for aggregate spend milestones
  • Tiered monthly discounts on capitalization table management software
  • Increased discounts with each quarterly IRC 409A valuation
  • Dedicated manager for each Biocom California member

Case Study:

409A and HSR Compliance

A world renowned biomedical scientist and entrepreneur brought together existing biotechnology assets to create a new company aiming to harness the power of placenta derived cells issues to amplify the body’s ability to fight disease and regenerate itself. Prior to closing on of the asset contributions and the financing, Economics Partners was engaged to value the company’s common stock to comply with IRS 409A. After the financing and asset contributions, EP engaged to provide an estimate of the fair market value of the contributed assets from the Public Company to comply with anti trust reporting purposes under the Hart Scott Rodino Act.

View Case Study

Case Study:

Purchase Price Allocation

A public biotech company acquired all of the outstanding stock of a private pharmaceutical company in which the private pharmaceutical company would own a majority of the shares outstanding of the combined company (reverse merger transaction). Economics Partners was engaged to allocate the purchase price to the acquired assets to comply with fair value reporting requirements.

View Case Study

Power up your savings

Connect With Biocom Purchasing Group Contracts

Related Articles

View More